ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,715
0,61%
Bitcoin
66 888,39
2,53%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sarepta Therapeutics Inc New (SRPT)

  7. Sarepta Therapeutics Inc New (SRPT) Actualités

SRPT

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics Inc New
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SRPT
DateHeureSourceTitreSymboleSociété
07/05/202402h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SRPTSarepta Therapeutics Inc New
07/05/202402h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SRPTSarepta Therapeutics Inc New
03/05/202416h07Business WireGene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global HealthNASDAQ:SRPTSarepta Therapeutics Inc New
01/05/202422h05Business WireSarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:SRPTSarepta Therapeutics Inc New
01/05/202400h38Business WireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SRPTSarepta Therapeutics Inc New
24/04/202414h30Business WireSarepta Therapeutics to Announce First Quarter 2024 Financial ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
08/03/202423h38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SRPTSarepta Therapeutics Inc New
04/03/202414h30Business WireSarepta Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:SRPTSarepta Therapeutics Inc New
29/02/202415h00Business WireSarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship ProgramNASDAQ:SRPTSarepta Therapeutics Inc New
28/02/202422h05Business WireSarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:SRPTSarepta Therapeutics Inc New
21/02/202414h30Business WireSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
16/02/202413h00Business WireSarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS IndicationNASDAQ:SRPTSarepta Therapeutics Inc New
13/02/202419h34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SRPTSarepta Therapeutics Inc New
10/02/202400h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SRPTSarepta Therapeutics Inc New
29/01/202413h00Business WireSarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51NASDAQ:SRPTSarepta Therapeutics Inc New
16/01/202415h02Business WireSarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4NASDAQ:SRPTSarepta Therapeutics Inc New
08/01/202418h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRPTSarepta Therapeutics Inc New
08/01/202417h55Business WireSarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product RevenueNASDAQ:SRPTSarepta Therapeutics Inc New
02/01/202414h30Business WireSarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SRPTSarepta Therapeutics Inc New
22/12/202314h00Business WireSarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory StatusNASDAQ:SRPTSarepta Therapeutics Inc New
02/11/202313h30Business WireSarepta Therapeutics to Present at the UBS Biopharma ConferenceNASDAQ:SRPTSarepta Therapeutics Inc New
01/11/202321h05Business WireSarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:SRPTSarepta Therapeutics Inc New
01/11/202321h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SRPTSarepta Therapeutics Inc New
31/10/202322h30KR Market News연준 결정 앞두고 뉴욕 증시 상승; 투자자들은 실적 주목NASDAQ:SRPTSarepta Therapeutics Inc New
30/10/202322h17Dow Jones NewsSarepta Therapeutics to Request Expansion of Elevidys to All Age Groups Following Study ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
30/10/202321h01Business WireSarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular DystrophyNASDAQ:SRPTSarepta Therapeutics Inc New
25/10/202314h30Business WireSarepta Therapeutics to Announce Third Quarter 2023 Financial ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
07/09/202315h00Business WireSarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic YearNASDAQ:SRPTSarepta Therapeutics Inc New
05/09/202314h30Business WireSarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:SRPTSarepta Therapeutics Inc New
30/08/202314h40PR Newswire (US)Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) TestNASDAQ:SRPTSarepta Therapeutics Inc New
 Showing the most relevant articles for your search:NASDAQ:SRPT

Dernières Valeurs Consultées

NASDAQ
SLGC
SomaLogic
NASDAQ
LILRV
Liberty Latin America
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés